← Leaderboards
Eti Yoles
Immunobrain Checkpoint Inc.
$5,749,685
Attributed
$5,749,685
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2021–23$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
Funding mix
By agency
NIH$5,749,685 · 1
By mechanism
R01$5,749,685 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposCognitive AbilityBrain PathologyClinical TrialsBiological MarkersAntibodiesAutoimmuneAmyloidAdverse EffectsBiologicalClinical ResearchBloodAntibody EngineeringBrainAgingCancer ImmunotherapyCancer TherapyCellsBehavior AssessmentAmyloidosisClinical DevelopmentClinical Outcome MeasuresCognitiveCognitive Function
Grant awards (4)
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$1,280,437
R01 · FY2023 · AG · contact PI
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$2,234,624
R01 · FY2022 · AG · contact PI
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$250,000
R01 · FY2022 · AG · contact PI
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$1,984,624
R01 · FY2021 · AG · contact PI